RxDoctor Payments Data

Nicholas Manuel

Internal Medicine · Jefferson, LANPI 1275037939

Payments from drug & device makers

$2,615in general payments, 2019–2025

Across 27 payments — averaging $96.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$571
  • Dexcom, Inc.$412
  • Novo Nordisk$390
  • Amgen$359
  • Corcept Therapeutics$352
  • Averitas Pharma Inc.$168
  • plus $363 from 4 others

What the payments were for

  • Food & beverage$2,615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,615 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$6,516
Medicare patients
62
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$53,079
ForteoTeriparatide12$48,390
TrulicityDulaglutide14$13,533
OzempicSemaglutide11$12,249
Cinacalcet Hcl18$7,976
Novolog FlexpenInsulin Aspart19$2,182
SynthroidLevothyroxine Sodium23$1,274
Nano 2nd Gen Pen NeedlePen Needle, Diabetic21$1,216
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,015
Levothyroxine Sodium139$903
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic13$898
Hydrocortisone20$688
Methimazole24$336
Spironolactone11$79
Alendronate Sodium11$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Forteo, Trulicity$571$115,00275 claims
Novo NordiskOzempic$390$12,24911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Jefferson

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →